ResultsIQ

ResultsIQ › Latest results › Hester Biosciences Limited

Hester Biosciences Limited Q2 FY26 results press release summary

NSE: HESTERBIO · BSE: 524669

Results press release of 12 Nov 2025, summarised by AI from the filing.

Hester Q2 FY26 standalone PAT fell 23% to ₹72.09 mn while consolidated PAT rose 71% to ₹143.31 mn.

Key takeaways

  1. Animal Healthcare recovery Business expected to regain momentum as government immunisation programmes resume later in the financial year, particularly in Q4 FY26.
  2. Poultry growth Poultry Healthcare divisional product sales grew 18% in Q2 FY26, driven by volume gains and sustained demand for core vaccines.

Original filing on BSE

Hester Biosciences Limited Q1 FY27 results

As filed: Revenue ₹77.2 cr (−8% year on year), EBITDA ₹22.8 cr (−1% year on year), PAT ₹96.7 cr (−25% year on year), EBITDA margin 29.5% (+211 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q4 FY26: Revenue ₹100 cr (+22% year on year), EBITDA ₹34.3 cr (+81% year on year), PAT ₹16.6 cr (+300% year on year), EBITDA margin 34.3% (+1,000 bps). Score 87 of 100, Above trend. Revenue and profit before exceptional items growth were well above the company's own trend; EBITDA growth was above it. EBITDA margin rose 1000 bps year on year. Tax rate 37%. Revenue grew on the previous quarter, against its usual seasonal pattern. Share price after the results: +12.2% in 28 days (Nifty 500: −0.1%).
  • Q3 FY26: Revenue ₹77.4 cr (+23% year on year), EBITDA ₹17.8 cr (+300% year on year), PAT ₹9.3 cr (−15% year on year), EBITDA margin 23.0% (+1,000 bps). Score 71 of 100, Above trend. Revenue and EBITDA growth were well above the company's own trend; profit growth was below it. EBITDA margin rose 1000 bps year on year. Consolidated profit -15% but standalone +167%. Profit fell 34% from last quarter. Share price after the results: +6.5% in 28 days (Nifty 500: +0.1%).
  • Q2 FY26: Revenue ₹71.0 cr (−15% year on year), EBITDA ₹11.0 cr (−42% year on year), PAT ₹14.0 cr (+75% year on year), EBITDA margin 15.5% (−713 bps). Score 21 of 100, Below trend. Revenue and EBITDA growth were well below the company's own trend; profit growth was above it. EBITDA margin fell 713 bps year on year. Other income 67% of PBT. Consolidated profit +75% but standalone -22%. Revenue fell 15% from last quarter. Profit rose ₹6.0 cr on a year ago, more than the ₹4.0 cr it added the year before. Share price after the results: −2.1% in 30 days (Nifty 500: +0.2%).
  • Q1 FY26: Revenue ₹84.0 cr (+2% year on year), EBITDA ₹23.0 cr (+28% year on year), PAT ₹17.0 cr (+143% year on year), EBITDA margin 27.4% (+543 bps). Score 62 of 100, In line with trend. Revenue growth was in line with the company's own trend; EBITDA growth was above it; profit growth was well above it. EBITDA margin rose 543 bps year on year. Consolidated profit +143% but standalone +0%. Share price after the results: +3.9% in 28 days (Nifty 500: −2.0%).
  • Q4 FY25: Revenue ₹82.0 cr (+4% year on year), EBITDA ₹19.0 cr (+19% year on year), PAT ₹2.0 cr (−67% year on year), EBITDA margin 23.2% (+292 bps). Score 39 of 100, Below trend. Revenue growth was in line with the company's own trend; EBITDA growth was above it; profit growth was well below it. EBITDA margin rose 292 bps year on year. Tax rate 100%. Consolidated profit -67% but standalone +43%. Profit fell 82% from last quarter. Share price after the results: +10.0% in 28 days (Nifty 500: +6.1%).
  • Q3 FY25: Revenue ₹63.0 cr (−6% year on year), EBITDA ₹4.0 cr (−60% year on year), PAT ₹11.0 cr (+175% year on year), EBITDA margin 6.4% (−858 bps). Score 29 of 100, Below trend. Revenue growth was below the company's own trend; EBITDA growth was well below it; profit growth was well above it. EBITDA margin fell 858 bps year on year. Other income 67% of PBT. Consolidated profit +175% but standalone -33%. Revenue fell 25% from last quarter.
  • Q2 FY25: Revenue ₹84.0 cr (+20% year on year), EBITDA ₹19.0 cr (+46% year on year), PAT ₹8.0 cr (+100% year on year), EBITDA margin 22.6% (+405 bps). Score 86 of 100, Above trend. EBITDA margin rose 405 bps year on year. Not enough history for a trend yet: scored on growth alone.

Past price moves after results do not indicate future moves. Not a recommendation.

Hester Biosciences Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.